ORIC Pharmaceuticals (NASDAQ:ORIC) has announced a supply agreement with Janssen Research & Development to evaluate ORIC-114, a brain penetrant, oral bioavailable, irreversible EGFR/HER2 inhibitor, in combination with subcutaneous (SC) amivantamab, Johnson & Johnson’s fully-human EGFR-MET bispecific antibody. The combination will be studied as a first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Under the terms of the agreement, ORIC will conduct and sponsor the trial, while Johnson & Johnson will supply SC amivantamab. ORIC retains development and commercial rights to ORIC-114 and remains free to explore additional combination therapies. The company plans to initiate its Phase 1b trial in the first quarter of 2025 to evaluate the safety and tolerability of ORIC-114 in combination with SC amivantamab for the specified patient population.
According to ORIC, the primary objective of the trial is to determine the provisional recommended Phase 2 dose for the combination. Additional objectives include the evaluation of efficacy and further characterization of the safety profile of ORIC-114 in combination with SC amivantamab. Initial data is expected to be reported by mid-2026.
